CEL-SCI (CVM) News Today $9.52 -0.35 (-3.55%) Closing price 04:00 PM EasternExtended Trading$9.54 +0.02 (+0.16%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period CEL-SCI Co. (NYSE:CVM) Short Interest UpdateSeptember 10, 2025 | marketbeat.comMAI Capital Management Buys 366,880 Shares of CEL-SCI Co. $CVMSeptember 9, 2025 | marketbeat.comCEL-SCI Announces Closing of $10 Million Public OfferingAugust 29, 2025 | businesswire.comCEL-SCI stock falls after pricing $10M public offering at discountAugust 28, 2025 | ca.investing.comCEL-SCI (NYSE:CVM) Trading Up 10.9% - Time to Buy?August 28, 2025 | marketbeat.comCEL-SCI Announces Pricing of $10 Million Public OfferingAugust 27, 2025 | businesswire.comCEL-SCI Announces Proposed Public OfferingAugust 27, 2025 | businesswire.comCEL-SCI Co. (NYSE:CVM) Sees Large Decline in Short InterestAugust 19, 2025 | marketbeat.comCEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last yearAugust 14, 2025 | msn.comCEL-SCI files for breakthrough designation for Multikine in Saudi ArabiaAugust 13, 2025 | msn.comCEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA TimelineAugust 13, 2025 | businesswire.comCEL-SCI (NYSE:CVM) Shares Up 15.5% - Should You Buy?August 3, 2025 | marketbeat.comRobert Eugene Watson Purchases 2,919 Shares of CEL-SCI Co. (NYSE:CVM) StockJuly 30, 2025 | insidertrades.comCEL-SCI Co. (NYSE:CVM) CEO Geert R. Kersten Purchases 29,197 SharesJuly 29, 2025 | insidertrades.comCEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American RulesJuly 14, 2025 | businesswire.comCEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock OfferingJuly 11, 2025 | marketwatch.comCEL-SCI Shares Jump on Strategic Saudi Deal for Cancer Immunotherapy MultikineJuly 11, 2025 | msn.comCEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s ThrilledJuly 11, 2025 | msn.comCEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American RulesJuly 11, 2025 | finance.yahoo.comCEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American RulesJuly 11, 2025 | businesswire.comCEL-SCI stock soars after Saudi partnership for cancer drug MultikineJuly 11, 2025 | au.investing.comCEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck CancerJuly 11, 2025 | businesswire.comCEL-SCI Announces Closing of Public OfferingMay 23, 2025 | businesswire.comBiggest stock movers Thursday: SNOW, URBN, and moreMay 22, 2025 | msn.comCEL-SCI plummets 44%, prices $5M stock offeringMay 22, 2025 | msn.comCEL-SCI Announces Pricing of Public OfferingMay 21, 2025 | businesswire.comCEL-SCI Implements 1-for-30 Stock Split To Support Share PriceMay 21, 2025 | nasdaq.comCEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi ArabiaMay 21, 2025 | finance.yahoo.comCEL-SCI Announces Proposed Public OfferingMay 21, 2025 | businesswire.comCEL-SCI Corporation Announces a 1 for 30 Combination of Common StockMay 20, 2025 | finanznachrichten.deCEL-SCI Announces Combination of Common StockMay 19, 2025 | businesswire.comCEL-SCI Reports Fiscal Second Quarter 2025 Financial ResultsMay 15, 2025 | finance.yahoo.comCEL-SCI says publication supports strategy to seek early approval for multikineApril 10, 2025 | markets.businessinsider.comNew Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor ResponsesApril 8, 2025 | businesswire.comCEL-SCI publishes new data from Multikine studyMarch 26, 2025 | markets.businessinsider.comCEL-SCI Announces Closing of $2.5 Million OfferingMarch 18, 2025 | finance.yahoo.comCEL-SCI announces pricing of $2.56M common stock offeringMarch 18, 2025 | markets.businessinsider.comCEL-SCI Announces Pricing of $2.5 Million OfferingMarch 17, 2025 | businesswire.comJournal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...March 14, 2025 | businesswire.comJournal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...March 14, 2025 | businesswire.comCEL-SCI announces neoadjuvant nivolumab plus chemotherapy study publishedMarch 14, 2025 | markets.businessinsider.comCEL-SCI to initiate Multikine cancer trialFebruary 20, 2025 | markets.businessinsider.comCEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer TrialFebruary 20, 2025 | businesswire.comCEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 WeeksFebruary 19, 2025 | finance.yahoo.comCVM: Fiscal Year 2024 ResultsFebruary 11, 2025 | finance.yahoo.comCEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck CancerJanuary 14, 2025 | finance.yahoo.comCEL-SCI (AMEX:CVM) Stock Quotes, Forecast and News SummaryDecember 31, 2024 | benzinga.comWhat's Going On With Cel-Sci Shares Premarket On Monday?December 30, 2024 | benzinga.comCEL-SCI prices $5M public offering at 31c per shareDecember 30, 2024 | markets.businessinsider.comCEL-SCI prices $5 million offeringDecember 30, 2024 | msn.com Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVM Media Mentions By Week CVM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CVM News Sentiment▼1.540.92▲Average Medical News Sentiment CVM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CVM Articles This Week▼21▲CVM Articles Average Week Get the Latest News and Ratings for CVM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for CEL-SCI and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Neurogene News Today Lifecore Biomedical News Today Mereo BioPharma Group News Today Aurora Cannabis News Today Cartesian Therapeutics News Today Candel Therapeutics News Today Monopar Therapeutics News Today Neumora Therapeutics News Today Lexeo Therapeutics News Today Atea Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CVM) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVM Stock Alerts